Xilio Therapeutics (XLO)CEO bought ~$25K

~$25K

Approx. value · 36K sh @ $0.6801

281K

Holds after · shares reported

Traded

Jun 16, 2025

Filed

Jun 18, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jun 16, 2025 · this disclosureInsiderCEO purchased ~$25K of XLO shares in the open market

What came next

1. Jun 16, 2025InsiderDirector purchased ~$31K of XLO shares in the open market
2. Jun 17, 2025InsiderDirector purchased ~$17K of XLO shares in the open market
3. Oct 2, 2025Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“On October 2, 2025, Xilio Therapeutics, Inc. (the “Company”) received approval from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) to transfer the listing of the Company’s common stock from The Nasdaq Global Select Market to The Nasdaq Capital Market.”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Xilio Therapeutics

OQRO holds no insider, Congress, fund or contract record for Xilio Therapeutics dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its XLO page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Xilio Therapeutics

• SEC Form 4Mar 30, 2026
• SEC Form 4Jan 5, 2026
• SEC Form 4Jan 5, 2026
• SEC Form 4Jun 18, 2025
• SEC Form 4Jun 18, 2025
• SEC Form 4Jan 3, 2025

Everything OQRO holds on this company is on its XLO page.